Efficacy and safety of isradipine in hypertension

Alexander M Shepherd, A. A. Carr, M. Davidov, J. Hamilton, H. Schnaper, M. Velasquez, B. Brockway, L. M. Prisant, B. Hamilton, L. Gonasun

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.

Original languageEnglish (US)
Pages (from-to)580-585
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume13
Issue number4
StatePublished - 1989

Fingerprint

Isradipine
Blood Pressure
Hypertension
Safety
Posture
Calcium Channel Blockers
Verapamil
Vasodilation
Pharmaceutical Preparations
Multicenter Studies
Heart Rate
Calcium
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Shepherd, A. M., Carr, A. A., Davidov, M., Hamilton, J., Schnaper, H., Velasquez, M., ... Gonasun, L. (1989). Efficacy and safety of isradipine in hypertension. Journal of Cardiovascular Pharmacology, 13(4), 580-585.

Efficacy and safety of isradipine in hypertension. / Shepherd, Alexander M; Carr, A. A.; Davidov, M.; Hamilton, J.; Schnaper, H.; Velasquez, M.; Brockway, B.; Prisant, L. M.; Hamilton, B.; Gonasun, L.

In: Journal of Cardiovascular Pharmacology, Vol. 13, No. 4, 1989, p. 580-585.

Research output: Contribution to journalArticle

Shepherd, AM, Carr, AA, Davidov, M, Hamilton, J, Schnaper, H, Velasquez, M, Brockway, B, Prisant, LM, Hamilton, B & Gonasun, L 1989, 'Efficacy and safety of isradipine in hypertension', Journal of Cardiovascular Pharmacology, vol. 13, no. 4, pp. 580-585.
Shepherd AM, Carr AA, Davidov M, Hamilton J, Schnaper H, Velasquez M et al. Efficacy and safety of isradipine in hypertension. Journal of Cardiovascular Pharmacology. 1989;13(4):580-585.
Shepherd, Alexander M ; Carr, A. A. ; Davidov, M. ; Hamilton, J. ; Schnaper, H. ; Velasquez, M. ; Brockway, B. ; Prisant, L. M. ; Hamilton, B. ; Gonasun, L. / Efficacy and safety of isradipine in hypertension. In: Journal of Cardiovascular Pharmacology. 1989 ; Vol. 13, No. 4. pp. 580-585.
@article{22c0e9364324420abe9e3e437a412b50,
title = "Efficacy and safety of isradipine in hypertension",
abstract = "Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.",
author = "Shepherd, {Alexander M} and Carr, {A. A.} and M. Davidov and J. Hamilton and H. Schnaper and M. Velasquez and B. Brockway and Prisant, {L. M.} and B. Hamilton and L. Gonasun",
year = "1989",
language = "English (US)",
volume = "13",
pages = "580--585",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of isradipine in hypertension

AU - Shepherd, Alexander M

AU - Carr, A. A.

AU - Davidov, M.

AU - Hamilton, J.

AU - Schnaper, H.

AU - Velasquez, M.

AU - Brockway, B.

AU - Prisant, L. M.

AU - Hamilton, B.

AU - Gonasun, L.

PY - 1989

Y1 - 1989

N2 - Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.

AB - Of the calcium channel blocking drugs, only verapamil is approved in the United States for treatment of hypertension. Isradipine is a 1,4-dihydropyridine calcium blocker that may be given on a twice-daily basis. It causes peripheral vasodilation with minimal cardiodepressant activity. We undertook a double-blind, parallel group randomized, multicenter study of 203 hypertensive subjects to examine the efficacy and safety of isradipine in treatment of hypertension. Subjects were given 0, 2.5, 5, 7.5, or 10 mg isradipine twice daily for up to 5 weeks. There was a significant dose-response relationship between isradipine dose and decrease in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Isradipine 15 mg/day reduced supine pressure by 16/15 mm Hg in patients with starting DBP < 105 mm Hg and by 38/22 mm Hg in those with starting DBP ≥ 105 mm Hg. There was no significant orthostatic fall in blood pressure at any dose. Heart rate (HR) increased on an average by only a maximum of four beats/min. The drug was slightly more effective in the elderly in the standing position than in the young in the standing position. Adverse effects were mild, and only six patients were discontinued from the study because of adverse effects. Isradipine appears to be a safe, effective drug in monotherapy of hypertension at a wide range of patient ages.

UR - http://www.scopus.com/inward/record.url?scp=0024564926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024564926&partnerID=8YFLogxK

M3 - Article

C2 - 2470995

AN - SCOPUS:0024564926

VL - 13

SP - 580

EP - 585

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -